A Vaccine for Alzheimer’s Disease?

Posted on by

Alzheimer; News from the web:

Swiss biopharma AC Immune has made targeting Alzheimer’s disease, the leading form of dementia, a top priority. The company’s numerous candidates and platforms target several different proteins and pathways thought to have a central role in Alzheimer’s pathology. 2020 has brought mixed news for AC Immune. In July, the company announced that their candidate tau vaccine, ACI-35.030, had shown “encouraging” safety data at a lower dose and was to be progressed to a higher-dose group. However, September brought the disappointing news that their anti-tau antibody, semorinemab, did not meet its primary efficacy endpoints in a Phase 2 trial. To discuss AC Immune’s work, Technology Networks spoke to CEO Prof. Andrea Pfeifer.

https://www.technologynetworks.com/

Read all about it HERE

Fundraiser for Alzheimer

Posted on by

Alzheimer; News from the web:

Start a Facebook fundraiser and CVS Health will give $10
Support the Association by starting a #GivingTuesday Facebook fundraiser today, and CVS Health will kick off your efforts with a $10 donation. In addition, donations made to your fundraiser on #GivingTuesday (Dec. 1) are eligible for a match from Facebook. The funds you raise help to provide Alzheimer’s care and support and accelerate critical research.

Read all about it HERE

FDA does not approve new Alzheimer’s drug

Posted on by

Alzheimer; News from the web:

Government health advisers sharply criticized a closely watched Alzheimer’s drug on Friday, concluding there wasn’t enough evidence that the experimental drug slowed the brain-destroying disease.

The panel of outside experts for the Food and Drug Administration agreed that a pivotal study in patients failed to show “strong evidence” that the drug worked. The experts warned of multiple “red flags” with the data, which did not initially show any benefit until another analysis with later results.

Read all about it HERE